Contrasting Lisata Therapeutics (NASDAQ:LSTA) & Sangamo Therapeutics (NASDAQ:SGMO)

Lisata Therapeutics (NASDAQ:LSTA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Earnings & Valuation

This table compares Lisata Therapeutics and Sangamo Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170,000.00	54.06	-$16.59 million	($1.64)	-0.62
Sangamo Therapeutics	$39.55 million	0.78	-$122.93 million	($0.38)	-0.19

Lisata Therapeutics has higher earnings, but lower revenue than Sangamo Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 9.6% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Lisata Therapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Lisata Therapeutics and Sangamo Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1	2	0	0	1.67
Sangamo Therapeutics	2	1	1	0	1.75

Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Lisata Therapeutics.

Profitability

This table compares Lisata Therapeutics and Sangamo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Summary

Sangamo Therapeutics beats Lisata Therapeutics on 8 of the 14 factors compared between the two stocks.

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.